No. of coagulation-dyfunction in tigecycline (%) | No. of other AEs in tigecycline (%) | |
---|---|---|
Gender | ||
Male | 125 (56.05) | 520 (40.19) |
Female | 69 (30.94) | 501 (38.72) |
Missing | 29 (13.00) | 273 (21.10) |
Age | ||
< 65 | 69 (30.94) | 470 (36.32) |
≥ 65 | 98 (43.95) | 360 (27.82) |
Missing | 56 (25.11) | 464 (35.86) |
Reporter | ||
Healthcare workers | 130 (58.30) | 787 (60.82) |
Non-health care workers | 83 (37.22) | 457 (35.32) |
Unknown | 10 (4.48) | 50 (3.86) |
Year | ||
2005–2010 | 51 (22.87) | 420 (32.46) |
2011–2015 | 71 (31.84) | 418 (32.30) |
2016–2020 | 101 (45.29) | 456 (35.24) |
Outcome | ||
Death | 45 (20.18) | 340 (26.28) |
Life-threatening | 28 (12.56) | 61 (4.71) |
Disability | 0 (0.00) | 16 (1.24) |
Hospitalization | 35 (15.70) | 308 (23.80) |
Other serious | 107 (47.98) | 405 (31.30) |
Required intervention | 1 (0.45) | 4 (0.31) |
Missing | 7 (3.14) | 160 (12.36) |
Dosing regimen | ||
Loading dose | 28 (12.56) | 86 (6.64) |
Non-loading dose | 121 (54.26) | 305 (23.57) |
Standard maintenance dosea | 111 (49.78) | 481 (37.17) |
High maintenance dosec | 34 (15.25) | 124 (9.58) |
Time to event | 10 (IQR 6.75–13) | |
Total | 223 | 1294 |